Bausch Health Companies Inc Stock Price, News & Analysis

Bausch Health Companies (NYSE/TSX: BHC) announced six poster presentations at the virtual American Academy of Dermatology (AAD) Annual Meeting, running from April 23-25, 2021. Highlights include new analyses of ARAZLO® (tazarotene) Lotion, focusing on efficacy results from Phase 3 studies for moderate-to-severe acne. Presentations will also cover DUOBRII® (halobetasol propionate and tazarotene) Lotion's effectiveness and quality of life impacts in psoriasis, alongside evaluations of SILIQ® (brodalumab) Injection's long-term efficacy and safety. Scott Hirsch emphasized the commitment to demonstrating clinical benefits.

Bausch Health Companies Inc. announced on April 16, 2021, that its VYZULTA® (latanoprostene bunod ophthalmic solution) has received regulatory approval from ANVISA in Brazil. This marks the tenth approval for VYZULTA, which is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. With approvals in ten markets, including the U.S. and several Latin American countries, the company aims to address critical unmet medical needs in glaucoma treatment. Thomas J. Appio emphasized the commitment to further regulatory approvals.

Bausch Health and Novaliq announced successful results from the first Phase 3 trial (GOBI) of NOV03 for treating dry eye disease associated with meibomian gland dysfunction. The trial met both co-primary endpoints, achieving statistical significance in corneal staining and dryness scores at day 15, with continued positive results through day 57. Over 16 million U.S. adults suffer from dry eye disease, making this drug significant. Further studies (MOJAVE and KALAHARI) will assess safety and efficacy, potentially leading to FDA filing in 2022.

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the release of its first-quarter 2021 financial results on May 4, 2021, at 8:00 a.m. EDT. A conference call will be held to discuss these results along with a business update. Interested participants can access the call via a provided webcast link. Bausch Health focuses on developing health care products across various therapeutic areas, including eye health and gastroenterology. More information is available on their website.

Bausch Health Companies Inc. launched ENVIVE™, a daily probiotic supplement, on April 8, 2021, targeting occasional gastrointestinal symptoms like diarrhea and bloating. The product aims to strengthen the gut barrier and has shown effectiveness in clinical trials, with 85% of participants reporting improved GI well-being. Priced at $16.99, ENVIVE™ is available at major retailers such as Target and CVS. This launch reflects Bausch Health's commitment to addressing consumer health needs, particularly as 61% of Americans experience GI issues.

Bausch + Lomb announced the FDA approval of ClearVisc™, a dispersive ophthalmic viscosurgical device (OVD) designed for ophthalmic surgeries, particularly cataract procedures. This innovative OVD provides enhanced corneal protection and visibility, utilizing Sorbitol for superior free radical protection. In clinical trials with 372 subjects, ClearVisc™ demonstrated non-inferior safety and efficacy compared to VISCOAT®, with excellent postoperative outcomes. This approval reflects Bausch + Lomb's commitment to advancing eye health technology and meeting surgical needs.

Bausch Health Companies announced a $100 million debt reduction plan through the redemption of its 7.00% Senior Secured Notes due 2024, scheduled for May 7, 2021. This action follows a previous redemption of $200 million in March 2021. The company aims to utilize cash generated from operations for this redemption, signifying improved liquidity. Bausch Health, focused on health care products across various therapeutic areas, continues to prioritize financial stability amid ongoing uncertainties due to the COVID-19 pandemic.